Immunotherapy for Lewis lung carcinoma utilizing dendritic cells infected with CK19 gene recombinant adenoviral vectors.
Dendritic cells (DCs) as 'professional' antigen-presenting cells (APCs) initiate and regulate immune responses to various antigens. DC-based vaccines have become a promising modality in cancer immunotherapy. Cytokeratin 19 (CK19) protein is expressed at high levels in lung cancer and many other tumor cells, suggesting CK19 as a potential tumor‑specific target for cancer immune therapy. We constructed a recombinant adenoviral vector containing the CK19 gene (rAd-CK19). DCs transfected with rAd-CK19 were used to vaccinate C57BL/6 mice bearing xenografts derived from Lewis lung carcinoma (LLC) cells. The transfected DCs gave rise to potent CK19-specific cytotoxic T lymphocytes (CTLs) capable of lysing LLC cells. Mice immunized with the rAd‑CK19-DCs exhibited significantly attenuated tumor growth (including tumor volume and weight) when compared to the tumor growth of mice immunized with rAd-c DCs or DCs during the 24-day observation period (P<0.05). The results revealed that the mice vaccinated with the rAd-CK19-DCs exhibited a potent protective and therapeutic antitumor immunity to LLC cells in the subcutaneous model along with an inhibitive effect on tumor growth compared to the mice vaccinated with the rAd-c DCs or DCs alone. The present study proposes a meaningful mode of action utilizing rAd-CK19 DCs in lung cancer immunotherapy.
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
Q F
QF
Sun
Department of Comprehensive Health Ⅱ, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, P.R. China.
X N
XN
Zhao
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
C L
CL
Peng
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
Y T
YT
Hao
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
Y P
YP
Zhao
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
N
N
Jiang
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
H
H
Xue
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
J Z
JZ
Guo
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
C H
CH
Yun
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
B
B
Cong
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, Shandong, P.R. China.
X G
XG
Zhao
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology*; D018827:Carcinoma, Lewis Lung / Q000276:immunology / Q000628:therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D015870:Gene Expression; D005822:Genetic Vectors; D057809:HEK293 Cells; D006801:Humans; D053539:Keratin-19 / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014161:Transduction, Genetic
D019496:Cancer Vaccines; D053539:Keratin-19